MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,904,344 | -23.0% | 280,090 | +21.7% | 0.07% | -18.8% |
| Q2 2023 | $53,150,790 | +1.7% | 230,090 | +6.6% | 0.08% | -1.2% |
| Q1 2023 | $52,272,440 | -15.2% | 215,770 | +1.6% | 0.09% | -21.1% |
| Q4 2022 | $61,617,173 | +350.5% | 212,290 | +0.9% | 0.11% | +354.2% |
| Q3 2022 | $13,679,000 | -9.7% | 210,482 | -0.6% | 0.02% | -7.7% |
| Q2 2022 | $15,155,000 | -31.0% | 211,719 | -5.4% | 0.03% | -10.3% |
| Q1 2022 | $21,961,000 | +17.9% | 223,816 | +1.8% | 0.03% | +31.8% |
| Q4 2021 | $18,633,000 | +5.7% | 219,884 | -0.5% | 0.02% | 0.0% |
| Q3 2021 | $17,625,000 | -18.0% | 220,889 | +0.1% | 0.02% | -15.4% |
| Q2 2021 | $21,497,000 | -14.3% | 220,687 | +2.9% | 0.03% | -18.8% |
| Q1 2021 | $25,081,000 | +7.2% | 214,425 | +1.9% | 0.03% | +10.3% |
| Q4 2020 | $23,388,000 | +13.7% | 210,380 | +21.4% | 0.03% | 0.0% |
| Q3 2020 | $20,571,000 | – | 173,260 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |